T3D Therapeutics Awarded SBIR Phase 2 Grant for Alzheimer’s Disease Drug Testing from The National Institute On Aging

T3D Therapeutics, Inc., a Research Triangle Park, NC-based developer of Alzheimerā€™s disease therapies announced today that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) Phase 2 grant for the clinical development of T3Dā€“959, a small molecule nuclear receptor agonist, for the treatment of Alzheimerā€™s disease. This award provides the company with an estimated $1.8 million in funding over two years. The award will support a Phase 2a clinical trial evaluating the efficacy and safety of T3Dā€“959 in mild-to-moderate Alzheimerā€™s patients.  T3Dā€“959 is a promising new, and potentially disease-modifying therapeutic for Alzheimerā€™s disease. The drug has displayed multi-faceted effectiveness on memory, motor function, inflammation, neuronal cell death, beta amyloid production and tau alteration in pre-clinical studies.

Commenting on the award, T3D Therapeuticsā€™ CEO John Didsbury said, ā€œThe National Institute on Agingā€™s support will enable us to test our novel approach to developing an Alzheimerā€™s disease drug therapy that has the potential to slow, stop or reverse the progression of disease. This award is reflective of the goal of the National Plan to address Alzheimerā€™s disease of finding effective therapies to prevent and effectively treat Alzheimerā€™s by
2025.”

Read the full press release: here.

get the latest